Retigabine

Drug Profile

Retigabine

Alternative Names: ADD-230001; AW21-360; D-20443; D-20443 dihydrochloride; D-23129; Ezogabine; GKE 841; GW-582892X; Potiga; Trobalt; WAY-143841

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Meda
  • Developer GlaxoSmithKline; Harvard University; Massachusetts General Hospital; The ALS Association; Valeant Pharmaceuticals International
  • Class Antiepileptic drugs; Carbamates; Fluorobenzenes; Phenylenediamines; Small molecules
  • Mechanism of Action GABA A receptor agonists; KCNQ potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Partial epilepsies
  • Phase III Lennox-Gastaut syndrome
  • Phase II Amyotrophic lateral sclerosis
  • Discontinued Postherpetic neuralgia

Most Recent Events

  • 05 Aug 2016 Meda has been acquired by Mylan
  • 12 May 2016 GlaxoSmithKline completes a phase III trial in Partial epilepsies (Adjunctive treatment) in USA, Argentina, Brazil, Canada and Mexico (NCT00310375)
  • 24 Mar 2015 Discontinued - Phase-II for Postherpetic neuralgia in USA and South Africa (PO, immediate-release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top